Opus Genetics IncIRD
Price$4.51

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $9.9M-10.3% YoYTTM through 30 Jun 2026
Net Income -$107.6MTTM through 30 Jun 2026
Free Cash Flow -$40.7MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-513.0%
Operating Margin-665.9%
Net Margin-1,091.8%

Returns

-115.7%ROA

Balance Sheet Health

Debt / Equity-0.03x
Current Ratio7.13x
Net Debt-$58.8Mnet cash position
Cash & Equivalents$88.8M

Quality Metrics

Altman Z-Score-2.11
Piotroski F-Score3 / 9
FCF Margin-412.6%
Rule of 40-358.6
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $14.2M
Diluted EPS-$1.29TTM
'20'21'22'23'24'25
FY2025: $-0.80

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.